Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
116 studies found for:    Immunodeficiency NOT AIDS | Open Studies
Show Display Options
RSS Create an RSS feed from your search for:
Immunodeficiency NOT AIDS | Open Studies
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Early Diagnosis and Stem Cell Transplantation for Severe Immunodeficiency Diseases
Condition: Severe Immunodeficiency Diseases
Intervention: Drug: Fludarabine, Busulfan, and Anti-Thymocyte Globulin
2 Recruiting Genetic Basis of Immunodeficiency
Condition: Severe Combined Immunodeficiency
Intervention:
3 Not yet recruiting Novel Testing Procedures
Condition: Immunodeficiencies
Intervention:
4 Unknown  Lymphocyte Immunophenotyping in Common Variable Immunodeficiency
Conditions: Common Variable Immunodeficiency;   Granulomatous Disease;   Bronchiectasis;   Immunoglobulin Treatment
Intervention:
5 Not yet recruiting ASIS for GAMMAGARD in Primary Immunodeficiency
Condition: Primary Immunodeficiency
Interventions: Drug: Gadolinium For abdomen;   Drug: Gadolinium For lower back;   Drug: Efficacy of Gammagard subcutaneously at Week 12;   Drug: Efficacy of Gammagard subcutaneously at Week 24;   Drug: Efficacy of Gammagard subcutaneously at Week 36;   Drug: Efficacy of Gammagard subdermally at Week 36;   Drug: Efficacy of Gammagard subdermally at Week 12;   Drug: Efficacy of Gammagard subdermally at Week 24;   Drug: Adverse Reactions of Gammagard subcutaneously at Week 12;   Drug: Adverse Reactions of Gammagard subcutaneously at Week 24;   Drug: Adverse Reactions of Gammagard subcutaneously at Week 36;   Drug: Adverse Reactions of Gammagard subdermally at Week 12;   Drug: Adverse Reactions of Gammagard subdermally at Week 24;   Drug: Adverse Reactions of Gammagard subdermally at Week 36
6 Not yet recruiting Generalized Neonatal Screening of Severe Combined Immunodeficiencies
Condition: Severe Combined Immunodeficiency, Atypical
Intervention: Biological: SCID screening
7 Not yet recruiting Clinical Characteristics and Genetic Profiles of Severe Combined Immunodeficiency in China
Condition: Severe Combined Immunodeficiency
Intervention: Genetic: gene sequencing
8 Unknown  "Prime Boost" Vaccination Strategy Combining Conjugated Anti- Pneumococcal Vaccine (s0) and Polysaccharide Anti- Pneumococcal Vaccine (s4) Compared to Polysaccharide Anti- Pneumococcal Vaccine Alone (s4) In Patients With Common Variable Immunodeficiency
Condition: Common Variable Immunodeficiency
Interventions: Biological: PPS;   Biological: PnCJ PPS
9 Recruiting Genetic Basis of Primary Immunodeficiencies
Condition: Immunologic Deficiency Syndrome
Intervention:
10 Recruiting Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants
Condition: Severe Combined Immunodeficiency Disease, X-linked
Interventions: Genetic: CL20-4i-EF/a-hyc-OPT;   Drug: Busulfan
11 Not yet recruiting A Two Cohort, Open-Label, Prospective, Multicenter Study of the Safety, Tolerability, Efficacy and Pharmacokinetics of ProMetic BioTherapeutics Immune Globulin Intravenous in Subjects With Primary Immunodeficiency Diseases
Condition: Primary Immunodeficiency
Intervention: Biological: Immune Globulin (Human) Intravenous
12 Recruiting Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting
Condition: Primary Immunodeficiency Disease (PIDD)
Intervention:
13 Unknown  Gene Therapy for X-linked Severe Combined Immunodeficiency (SCID-X1)
Condition: X-linked Severe Combined Immunodeficiency
Intervention: Genetic: Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) gammaretroviral vector pSRS11.EFS.IL2RG.pre
14 Recruiting Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Conditions: Primary Immune Deficiency Disorders;   Common Variable Immunodeficiency;   X-linked Agammaglobulinaemia;   Hyper-IgM Syndrome
Interventions: Biological: Gammaplex (5%);   Biological: Gammaplex 10
15 Recruiting Assessment of Immunoglobulins (IgG) in a Long-term Non-interventional Study
Conditions: Primary Immunodeficiency (PID);   Secondary Immunodeficiency (SID);   Neurological Autoimmune Disease
Intervention: Other: Immunoglobulin G (IgG)
16 Recruiting Gene Transfer for Severe Combined Immunodeficiency, X-linked (SCID-X1) Using a Self-inactivating (SIN) Gammaretroviral Vector
Condition: Severe Combined Immunodeficiency
Intervention: Biological: Gene transfer
17 Recruiting Gammanorm Quality of Life Study in Immunodeficient Patients Using Rapid Push or Pumps
Condition: Primary Immunodeficiency (PID)
Intervention: Biological: Gammanorm
18 Recruiting Immune Regulation in Patients With Common Variable Immunodeficiency and Related Syndromes
Condition: CVID
Intervention:
19 Recruiting Sirolimus Prophylaxis for aGVHD in TME SCID
Conditions: Severe Combined Immunodeficiency;   Transplacental Maternal Engraftment;   Stem Cell Transplant
Intervention: Drug: Sirolimus
20 Recruiting EZN-2279 in Patients With ADA-SCID
Conditions: ADA-SCID;   Adenosine Deaminase Deficiency;   Severe Combined Immunodeficiency
Intervention: Biological: EZN-2279

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years